CN101623283A - Medicinal composition for relieving asthma - Google Patents
Medicinal composition for relieving asthma Download PDFInfo
- Publication number
- CN101623283A CN101623283A CN200810116487A CN200810116487A CN101623283A CN 101623283 A CN101623283 A CN 101623283A CN 200810116487 A CN200810116487 A CN 200810116487A CN 200810116487 A CN200810116487 A CN 200810116487A CN 101623283 A CN101623283 A CN 101623283A
- Authority
- CN
- China
- Prior art keywords
- guaifenesin
- asthma
- oxtriphylline
- gram
- relieving asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a medicinal composition for relieving asthma, which is a composition formed by an active component formed by choline theophyllinate and guaifenesin, and a pharmaceutically acceptable auxiliary material. The composition can be prepared into oral preparations according to the preparation method, including syrups, dry suspensions, powder and granules, wherein the unit dosage of the choline theophyllinate is between 0.02 and 1 gram preferably between 0.1 and 0.2 gram, and the unit dosage of the guaifenesin is between 0.02 and 1 gram preferably between 0.1 and 0.2 gram.
Description
Technical field
The present invention relates to a kind of Pharmaceutical composition that is used to relieving asthma, is the compositions that the active component that formed by Oxtriphylline and guaifenesin and acceptable accessories form, and belongs to medical technical field.
Background technology
Cough, expectoration and asthma are the common symptoms of respiratory system disease, upper respiratory tract infection, and chronic bronchitis causes that etc. reason long-term frequent cough, expectoration, asthma not only influence patient's rest and sleep, also aggravates disease, and brings out other complication.Asthma is by the various kinds of cell chronic airway inflammation that participates in of mastocyte, eosinophilic granulocyte and T lymphocyte particularly; This kind inflammation can cause that bronchial muscular spasm, myxedema and secretions increase in the susceptible person, causes when breathing sluggish in air circulationly, shows as symptoms such as the panting of outbreak repeatedly, tachypnea, uncomfortable in chest, cough, how to take place at night or morning.Typical performance is ictal expiratory dyspnea with wheezing sound.Severe patient can be forced to take seat or be orthopnea, dry cough or cough up a large amount of white foam expectorant, even cyanosis etc. appears.Symptoms of asthma can be shown effect in several minutes, through a few hours to a couple of days, with bronchodilator or spontaneous remission.
The decapacitation of theophylline class suppresses PDE, improves outside the cAMP concentration in the smooth muscle cell, has the antagonism of adenosine receptor simultaneously; And can promote adrenergic secretion in the body; Strengthen the air flue cilium and remove function and antiinflammatory action.One of the medicine Oxtriphylline that is treatment asthma at present commonly used is a phosphodiesterase inhibitor, and its pharmacological action is similar to aminophylline, and the bronchial smooth muscle that can relax suppressed sensitive media release.In spasmolytic, also can alleviate the hyperemia and the edema of bronchial mucosa.Strengthen the contractility of respiratory muscle, reduce respiratory muscle fatigue.Strengthen myocardial contraction, increase cardiac output, low dosage is not generally accelerated heart rate.But Oxtriphylline to bronchiectatic activity than aminophylline a little less than, to the side effect of heart than aminophylline a little less than, gastrointestinal irritation is light, patient easily tolerates.Oral, injection all absorbs rapidly, and is widely distributed in the body, is mainly used in bronchial asthma, also is used for angina pectoris.
Guaifenesin is a stimulant expectorant, can stimulate gastric mucosa, causes that reflectingly the respiratory tract body of gland divides secret increase, makes the sputum dilution, is easy to expectoration, thereby produces phlegm-dispelling functions.And the sterilization antisepsis is arranged, this product also has antitussive, spasmolytic, anticonvulsant action, is used for excessive phlegm cough, pulmonary abscess, bronchiectasis and the Secondary cases asthma of chronic bronchitis.Many and other antitussive and antiasthmatic medicines share.Be used for the situation that mucus is difficult for expectoration.
Summary of the invention
The present invention relates to a kind of Pharmaceutical composition that is used to relieving asthma, it is the compositions that the active component that formed by Oxtriphylline and guaifenesin and acceptable accessories form.Said composition can be made oral formulations according to preparation method of the present invention.Comprise syrup, dry suspension, powder and granule.Wherein the unit consumption of Oxtriphylline is 0.02-1g, preferred 0.1-0.2g; The unit consumption of guaifenesin is 0.02-1g, preferred 0.1-0.2g.
Compositions of the present invention with symptoms such as effective relieving asthma patient excessive phlegm cough, dyspnea out of breath, in addition for bronchitis or other diseases with the symptom of panting, also can play certain therapeutical effect.A 0.2～0.3g, every day 3-4 time.
The specific embodiment
Embodiment 1 syrup
Prescription:
Preparation method:
Oxtriphylline, guaifenesin are dissolved in the suitable quantity of water, are heated to 80-100, stir and make it dissolving, get clear aqueous solution; Sucrose is made 500ml syrup sterilized solution, and adding sodium benzoate, sodium sulfite make it dissolving; Aqueous solution is added in the syrup, add correctives at last, filter, insulation adds water to recipe quantity, stirs evenly packing.
Embodiment 2, powder
Prescription:
Preparation method:
Oxtriphylline, guaifenesin, xylitol are crossed 80 mesh sieves, mix homogeneously respectively; Pack after adding micropowder silica gel, stevioside mix homogeneously, promptly
Embodiment 3, dry suspension
Preparation method:
Earlier Oxtriphylline, guaifenesin, sucrose, sorbitol etc. are all crossed 80 mesh sieves, and mix homogeneously, with ethanol solution as binding agent system soft material, 40 mesh sieves are granulated, drying adopts 50 mesh sieve granulate, adds HPMC, silicon dioxide and mix homogeneously in the gained granula subtilis, the packing of every bag 1 gram gets final product.
Embodiment 4: granule
Prescription:
Preparation method:
Oxtriphylline, guaifenesin, mannitol, glucose were waited 80 mesh sieves, mix homogeneously; With the 75% alcoholic solution system soft material of 5%PVPk-30,16 orders are granulated, drying, and 12 order granulate add other adjuvant, and as mix homogeneously such as orange flavor, acesulfame potassiums, packing is promptly.
Embodiment 5, pharmacological evaluation:
Experiment purpose:
Evaluation the influence experimental technique of oral liquid (Oxtriphylline+guaifenesin) of relievining asthma to guinea pig bronchial smooth muscle relaxation and antiasthmatic effect:
30 Cavia porcelluss are divided into 3 groups, and 10 every group, irritate stomach respectively, matched group gives double distilled water, and the medication group gives compound antiasthmatic oral liquid and Oxtriphylline 0.2gkg respectively
-1, irritate the long-pending 5mLkg that is of body of stomach
-1, draw the method for breathing heavily by whole animal behind the 1h animal is put into the lucite spray tank, spray into 2% acecoline and 0.1% histamine equal-volume mixed liquor with 60kPa pressure, last 8S (spouting liquid 12.5mLmin
-1), observe from spraying and begin to animal because of till bronchospasm breathes that being the devil twitches and fall.Tic number of animals and incubation period take place in record, and the longest observation 360S surpasses and this moment the tiqueur do not taken place, counts 360S.Postpone to take place with dyspnea, time lengthening is preceding more than 3 times to administration, is judged to be effectively.Observe relatively respectively to organize to draw to breathe heavily and reach the number of animals of generation tic of each group incubation period.
Experimental result:
The compound antiasthmatic oral liquid has obvious inhibitory action to the asthma that acecoline and histamine cause.8 Cavia porcelluss of matched group all dyspnea occurs and twitch and fall; Positive control albuterol group also demonstrates antiasthmatic effect preferably, sees Table 1.
Table 1 compound antiasthmatic oral liquid is to the influence of bronchial asthma (n=10, x ± s)
The administration group is compared with matched group, checks through t: * P＜0.01,
P＜0.05
Claims (6)
1. Pharmaceutical composition that is used to relieving asthma is characterized in that: be the compositions that the active component that formed by Oxtriphylline and guaifenesin and acceptable accessories form.
2. the described compositions of claim 1 is characterized in that: can be made into oral formulations.
3. the described compositions of claim 2, it is characterized in that: oral formulations comprises syrup, dry suspension, powder and granule.
4. the described compositions of claim 3, it is characterized in that: the unit consumption of Oxtriphylline is 0.02-1g, preferred 0.1-0.2g.
5. the described compositions of claim 3, it is characterized in that: the unit consumption of guaifenesin is 0.02-1g, preferred 0.1-0.2g.
6. the described compositions of claim 1 is used for the treatment of various types of asthma, relief of symptoms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810116487A CN101623283A (en) | 2008-07-10 | 2008-07-10 | Medicinal composition for relieving asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810116487A CN101623283A (en) | 2008-07-10 | 2008-07-10 | Medicinal composition for relieving asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101623283A true CN101623283A (en) | 2010-01-13 |
Family
ID=41519378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810116487A Pending CN101623283A (en) | 2008-07-10 | 2008-07-10 | Medicinal composition for relieving asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101623283A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832671A (en) * | 2016-04-13 | 2016-08-10 | 中国药科大学 | Dry suspension for controlled-release of medicine and preparation method of dry suspension |
| CN111374982A (en) * | 2020-02-27 | 2020-07-07 | 佛山手心制药有限公司 | Pharmaceutical composition for eliminating phlegm and relieving asthma and application thereof |
-
2008
- 2008-07-10 CN CN200810116487A patent/CN101623283A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832671A (en) * | 2016-04-13 | 2016-08-10 | 中国药科大学 | Dry suspension for controlled-release of medicine and preparation method of dry suspension |
| CN111374982A (en) * | 2020-02-27 | 2020-07-07 | 佛山手心制药有限公司 | Pharmaceutical composition for eliminating phlegm and relieving asthma and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101953821A (en) | Medicinal composition taking levalbuterol and ambroxol as main active ingredients | |
| CN102961365A (en) | Terbutaline sulfate oral instant film and preparation method thereof | |
| CN102805746B (en) | A kind of act on respiratory system disease compound chemical medicine and preparation technology and application | |
| CN101322761B (en) | Medicament for treating tracheitis and bronchitic and preparation thereof | |
| CN101904827A (en) | Orally disintegrating tablet of ambroxol hydrochloride and preparation method thereof | |
| CN101623283A (en) | Medicinal composition for relieving asthma | |
| CN1559508A (en) | Medicine for preventing and curing laryngolaryngitis and its preparation method | |
| CN1284585C (en) | Medicine for treating acute and chronic pharyogolaryngitis, recurring oral cavity sore and its preparation method | |
| CN101982174A (en) | Formula of compound medicine preparation for relieving cough and preventing asthma and preparation method thereof | |
| CN102319208A (en) | Suspension composition for treating oral mucositis caused by chemoradiotherapy | |
| CN1981859A (en) | Chinese-medicinal extract with liver-clearing and phlegm-resolving functions and its production | |
| CN101612154A (en) | Contain the compositions of pivampicillin and preparation method, purposes | |
| CN102784137A (en) | Anti-obesity drug composition and application thereof | |
| CN101579342A (en) | Desloratadine-contained patulin composition | |
| CN102188574A (en) | Chinese medicine composition for treating influenza A virus bronchitis and preparation method thereof | |
| CN101849939A (en) | Medicinal composition taking ipratropium bromide and salbutamol as main active ingredients | |
| CN101084898B (en) | Compound chemical medicine with antitussive and phlegm-eliminating action and its preparation technology | |
| CN1212116C (en) | Sophorcarpidine alkaloid and decongestant compound medicine and its preparation method | |
| CN103830222A (en) | Application of baicalein in preparation of oral ulcer treatment medicines | |
| CN101214245A (en) | Composition containing ciclacillin or its derivatives and preparation thereof | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| US6998142B2 (en) | Composition and method for the prevention and treatment of asthma | |
| CN1304018C (en) | Cough-stopping throat-clearing medicament made from chrysanthemum flower | |
| CN102846605B (en) | Medicinal composition, as well as preparation process and application thereof | |
| CN109549946B (en) | Medicine for treating pharyngitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100113 |